Fiche publication
Date publication
août 2018
Journal
Trends in cardiovascular medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent
,
Dr NEBIGIL-DESAUBRY Canan
Tous les auteurs :
Nebigil CG, Désaubry L
Lien Pubmed
Résumé
Congenital heart disease is the most common birth defect, affecting 1.35 million newborns every year. Heart failure is a primary cause of late morbidity and mortality after myocardial infarction. Heart development is involved in several rounds of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET). Errors in these processes contribute to congenital heart disease, and exert deleterious effects on the heart and circulation after myocardial infarction. The identification of factors that are involved in heart development and disease, and the development of new approaches for the treatment of these disorders are of great interest. G protein coupled receptors (GPCRs) comprise 40% of clinically used drug targets, and their signaling are vital components of the heart during development, cardiac repair and in cardiac disease pathogenesis. This review focuses on the importance of EMT program in the heart, and outlines the newly identified GPCRs as potential therapeutic targets of reprogramming EMT to support cardiac cell fate during heart development and after myocardial infarction. More specifically we discuss prokineticin, serotonin, sphingosine-1-phosphate and apelin receptors in heart development and diseases. Further understanding of the regulation of EMT/MET by GPCRs during development and in the adult hearts can provide the following clinical exploitation of these pathways.
Mots clés
Apelin, Serotonin, Cardiac progenitor cells, Cardiac stem cells, Congenital heart disease, Epithelial to Mesenchymal Transformation (EMT), GPCR, Heart development, Heart failure, Prokineticin, Sphingosine-1-phosphate
Référence
Trends Cardiovasc. Med.. 2018 Aug 22;:
